IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:
Open original source